Last reviewed · How we verify
Fecal Microbial Transplantation — Competitive Intelligence Brief
phase 3
Biotherapeutic microbiota therapeutic
Gastroenterology / Infectious Disease / Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Fecal Microbial Transplantation (Fecal Microbial Transplantation) — ProgenaBiome. Fecal microbial transplantation (FMT) restores a healthy gut microbiome by transferring bacterial communities from a healthy donor to a patient with dysbiosis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fecal Microbial Transplantation TARGET | Fecal Microbial Transplantation | ProgenaBiome | phase 3 | Biotherapeutic microbiota therapeutic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Biotherapeutic microbiota therapeutic class)
- ProgenaBiome · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fecal Microbial Transplantation CI watch — RSS
- Fecal Microbial Transplantation CI watch — Atom
- Fecal Microbial Transplantation CI watch — JSON
- Fecal Microbial Transplantation alone — RSS
- Whole Biotherapeutic microbiota therapeutic class — RSS
Cite this brief
Drug Landscape (2026). Fecal Microbial Transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/fecal-microbial-transplantation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing